Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Monday that it has entered an agreement to acquire IDRx Inc, a Boston-based clinical-stage biopharmaceutical company, for up to USD1.15bn.
The acquisition includes IDRX-42, a selective KIT tyrosine kinase inhibitor (TKI) targeting gastrointestinal stromal tumours (GIST). GSK will pay USD1bn upfront, with an additional USD150m tied to regulatory milestones.
IDRX-42 is designed to address all primary and secondary KIT mutations that drive GIST progression, offering potential improvements in efficacy and tolerability over existing therapies. Recent phase I/Ib trial data demonstrated a 53% objective response rate in patients treated after one prior therapy, with a manageable safety profile.
GSK's expanding gastrointestinal cancer portfolio, which includes assets like dostarlimab and GSK5764227, underscores its focus on targeted mechanisms to address unmet medical needs. The acquisition aligns with GSK's growth ambitions through 2031 and beyond.
GIST is the most common subtype of soft tissue sarcoma, affecting up to 120,000 patients globally each year. Mutations in the KIT gene drive 80% of cases, with most first-line patients developing resistance mutations that lead to relapse. IDRX-42 has FDA Fast Track and Orphan Drug designations, highlighting its potential to fill critical gaps in treatment options.
The transaction, subject to regulatory approvals under the Hart-Scott-Rodino Act, also includes milestone payments and royalties to Merck KGaA, Darmstadt, Germany, for IDRX-42. Legal and financial advisory roles were provided by Centerview Partners, Goodwin Procter, and Leerink Partners.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024